New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

This information is clinically relevant because if a patient continues to have MRD-positive status after treatment with isatuximab-VRd, then a change of therapy may prolong progression-free survival.

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the ...

Over the past two decades the paradigm of multiple myeloma therapy has changed dramatically from conventional chemotherapy and autologous stem cell transplant (ASCT) to combination regimens of ...

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.